In summary, the current work advances the field by showing the reversibility of β-cell dedifferentiation at the ALDH1A3 activation stage and providing proof-of-principle in preclinical models of its pharmacological inhibition as a treatment for diabetes. Here, ALDH1A3 is linked to diabetes mellitus.